RxDoctor Payments Data

Laszlo Mate, MD

Neurology · North Palm Beach, FLNPI 1457351934

Payments from drug & device makers

$135,779in general payments, 2019–2025

Across 411 payments — averaging $330.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$88K
  • Acadia Pharmaceuticals Inc$16K
  • Novartis$14K
  • Eli Lilly$9K
  • Ipsen Biopharmaceuticals, Inc$1K
  • Pfizer$983
  • plus $7K from 48 others
$66,685in research payments, 2019–2025

Across 27 payments — averaging $2469.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$57K
  • Eli Lilly$5K
  • Avanir Pharmaceuticals, Inc.$3K
  • Ipsen Biopharmaceuticals, Inc$2K

What the payments were for

  • Food & beverage$7,885100%
  • Education$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC10$87,632
Acadia Pharmaceuticals Inc2$15,736
Novartis10$13,739
Eli Lilly2$9,334
Ipsen Biopharmaceuticals, Inc3$1,086
Pfizer32$983
Supernus Pharmaceuticals, Inc.56$789
UCB, Inc.22$731
Biogen32$648
Neurelis, Inc.28$584
Eisai Inc.21$536
AbbVie(2 entities)29$477
Lilly USA, LLC18$386
Sunovion Pharmaceuticals Inc.13$333
Teva Pharmaceuticals USA, Inc.12$298
Sanofi4$227
Biohaven Pharmaceutical Holding Company Ltd.11$186
Adlon Therapeutics L.p.9$152
EMD Serono, Inc.8$144
Otsuka America Pharmaceutical, Inc.6$133
Biohaven Pharmaceuticals, Inc.9$123
Argenx US, Inc.4$109
Sumitomo Pharma America, Inc.5$102
Corium, LLC5$99
AstraZeneca(2 entities)4$93
Johnson & Johnson4$91
Ironshore Pharmaceuticals Inc.4$81
Amgen4$81
Tris Pharma Inc5$80
Harmony Biosciences LLC2$69
E.r. Squibb & Sons, L.L.C.3$66
Bristol Myers Squibb3$65
Upsher-smith Laboratories LLC4$64
Jazz Pharmaceuticals Inc.3$54
Aucta Pharmaceuticals, Inc.3$53
Merz Pharmaceuticals, LLC2$45
Collegium Pharmaceutical, Inc.2$36
Tanabe Pharma America, Inc.1$28
Viiv Healthcare Company1$25
Immedica Pharma US, Inc.1$24
Acorda Therapeutics, Inc1$24
Abbott1$23
Avadel CNS Pharmaceuticals, LLC1$22
SK Life Science, Inc.1$21
Mirum Pharmaceuticals, Inc.1$21
Mallinckrodt Hospital Products Inc.1$20
Aquestive Therapeutics, Inc.1$20
Alnylam Pharmaceuticals Inc.1$18
Impel Pharmaceuticals Inc.1$17
Neurocrine Biosciences, Inc.1$15
Cranial Technologies, Inc1$15
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$14
Takeda Pharmaceuticals U.S.A., Inc.1$14
Zyla Life Sciences, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$135,779 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$30,843
Medicare patients
73
Services billed
387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina17$25,084
MyrbetriqMirabegron12$8,746
Rivastigmine49$5,540
Carbamazepine ErCarbamazepine16$2,988
Donepezil Hcl244$2,624
Primidone49$2,032
Pregabalin140$1,888
Gabapentin173$1,878
Lacosamide28$1,612
Memantine Hcl95$1,382
Levetiracetam65$1,284
Carbidopa-LevodopaCarbidopa/Levodopa55$1,126
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen38$1,002
Phenobarbital13$954
Oxcarbazepine13$946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$477$25,08417 claims
Upsher-smith Laboratories LLCTopiramate$64$49623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.

Other neurology in North Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →